Introduction
More than 50,000 new pancreatic cancer (PC) cases and >40,000 cancer-related mortalities due to PC are expected in the USA in 2016. 1, 2 The 5-year survival rate for all stages of PC combined is 8%. Although those with resectable disease have a more favorable prognosis (5-year survival ≈29%), ≈52% of patients are diagnosed with metastatic disease, which confers a less favorable outlook (5-year survival ≈3%).
2 Since the approval of gemcitabine (Gem) in 1997, no phase III trial in advanced/metastatic disease had demonstrated a clinically and statistically significant improvement in overall survival (OS) over Gem alone 3 until recently. The treatment landscape for metastatic 6 nab-P/Gem and FOLFIRINOX have not been approved for earlier-stage disease; however, numerous trials are exploring their utility. The NCCN recommends chemotherapy for unresectable locally advanced PC (LAPC) and chemoradiation for selected patients, preferably after induction chemotherapy for tumor control. 6 Currently, no clear evidence exists to support the use of nab-P/Gem over FOLFIRINOX or vice versa, and several trials are investigating their efficacy and safety. 8 A population-based study of >3,000 patients showed that nab-P/Gem is the most commonly used chemotherapy regimen for the first-line treatment of MPC in the USA, 9 possibly due to the toxicity profile of FOLFIRINOX, which limits its use to younger/fitter patients. The extensive use of nab-P/Gem in both academic and community settings coupled with >100 current and active clinical trials in PC warrants a comprehensive review of clinical data to gain a better understanding of how this regimen is being used for the treatment of PC and associated outcomes. The overall goal of this review is to summarize recent data regarding the safety and efficacy of regimens that include nab-P/Gem for patients with PC.
Methods
The search terms "nab-paclitaxel and (pancreatic or pancreas)" were entered in PubMed to retrieve publications from January 1, 2011 to June 30, 2016 . Abstracts from the annual meetings of the American Society of Clinical Oncology (ASCO) 2011-2016, the Gastrointestinal Cancers Symposium (ASCO GI) 2011-2016, the European Cancer Organisation/ESMO 2011-2015, the ESMO World Congress on Gastrointestinal Cancer 2015 and 2016, and the Italian Association of Medical Oncology (2014) were searched using the term "nab-paclitaxel." Clinical trials and institutional analyses of nab-P in all stages of PC were included. Duplicates, electronic abstracts, case studies, cost studies, meta-analyses, and studies of the effects of eligibility criteria were excluded. The website www.clinicaltrials.gov was searched using the terms "nab-paclitaxel" OR "Abraxane" AND "pancreatic" AND "adenocarcinoma" to identify ongoing trials without results; only open, active, phase II-III trials with a sample size ≥100 were included.
Results

Studies of nab-P in advanced/ metastatic PC
Fifty studies evaluating nab-P in MPC were retrieved ( Figure 1 ; Table 1 ). Approximately one-half were retrospective analyses. MPACT was the only phase III study, and all other prospective trials were phase I or II. Two-thirds of studies evaluated nab-P in the first-line setting, and approximately one-third of those studies assessed nab-P/Gem with an additional agent. nab-P was most often evaluated at a dose of , which was given the first 3 of 4 weeks (qw 3/4). The tables in this systematic review cover MPC (Tables 1-3) , neoadjuvant treatment or locally advanced disease (Table 4) , and ongoing trials in all settings (Table 5) .
nab-P/Gem in MPC
Ten studies reported the median OS for first-line nab-P/Gem in patients with advanced PC; 5,10-18 Table 2 lists 8 of these studies with a population >45 patients. The most commonly used dose and schedule were those used in the MPACT trial:
nab-P 125 mg/m 2 plus Gem 1,000 mg/m 2 administered on a qw 3/4 schedule. 5, 14, 19, 20 Patients treated with this dose and schedule experienced a median OS ranging from 8.7 to 13.5 months 5, 18 and 1-year survival ranging from 35% to 62%. 5, 14, 19, 20 Most prospective studies evaluating this dose and schedule were single-arm trials.
nab-P/Gem in MPC -age
It may be expected that younger patients would experience longer survival and improved tolerability compared with older patients. However, most studies, including MPACT, suggest that older patients benefit from nab-P/Gem in terms of efficacy without increased risk of toxicity. Approximately 40% of patients enrolled in MPACT were >65 years. 5 Median OS was 9.6 and 7.7 months for patients <65 and ≥65 years, respectively, and the toxicity profiles were similar between age groups. 5 The combination in MPACT demonstrated significant OS benefit over Gem alone in both age groups: <65 years (HR, 0.65; P<0.001) and ≥65 years (HR, 0.80; P=0.048).
A study (N=37) including patients treated with first-line or ≥ second-line nab-P/Gem for MPC showed that OS was not significantly different between patients ≥66 years and those <66 years of age (median, 10.5 vs 9 months; P=0.49). 21 Similarly, a large Italian database review of patients (N=208) with advanced PC treated with nab-P/Gem demonstrated that age (≥75 vs <75 years) was not significantly associated with efficacy or toxicity with respect to median OS 64) , grade 3/4 neutropenia (25% vs 28%), and neurotoxicity (9% vs 12%). 22 Additionally, an exploratory analysis from MPACT showed that the percentages of patients requiring nab-P dose reductions were similar between age groups (42% for patients ≥65 years vs 40% for patients <65 years). 23 
nab-P/Gem in MPC -PS
Data on whether patients with a better PS might receive greater benefit from nab-P/Gem than patients with a poorer PS are inconclusive; however, similar to the literature in older patients, several studies suggest that less fit patients receive meaningful benefit from the regimen. Stratification of the MPACT population by Karnofsky PS (KPS) demonstrated significantly better OS in the fitter (KPS 90-100) versus less fit (KPS 70-80) group in the combination arm (median, 9.7 vs 7.6 months; HR, 0.76; P=0.009) and the Gem arm (median, 7.9 vs 4.3 months; HR, 0.57; P<0.001). 5 In the KPS 70-80 subpopulation, nab-P/Gem extended median OS by >3 months compared with Gem alone (7.6 vs 4.3 months; HR, 0.59; P<0.001).
A small phase I/II trial examined the effect of nab-P/ Gem in patients with an Eastern Cooperative Oncology Group (ECOG) PS of 2. 24 The results of the phase I portion suggest that these patients were able to receive the standard dose of nab-P/Gem; the relative dose intensity was 100% in 6 patients who received nab-P 125 mg/m 2 plus Gem 1,000 mg/m 2 qw 3/4. In a retrospective analysis of 39 patients with unresectable LAPC or MPC treated with nab-P/Gem, 25 patients with an ECOG PS of 1 survived longer than patients with an ECOG PS of 2 (median OS, 15 vs 7 months; P=0.032). 25 Similarly, the previously mentioned Italian retrospective analysis of patients with advanced PC (N=208) treated with nab-P/Gem showed a numerically shorter OS in the ECOG PS 2 versus ECOG PS 0-1 group (median, 8.7 vs 11.2 months; P=0.07), but the difference was not significant. 22 In addition, toxicities did not appear to be influenced by PS, because similar percentages of patients with PS 0-1 and PS 2 developed neutropenia (31% and 34%, respectively) and neurotoxicity (17% in each group). Collectively, these studies suggest that, although PS may affect OS, nab-P/Gem seems to be effective regardless of PS.
nab-P/Gem in MPC -real-world comparative effectiveness studies
Although clinical trials comparing nab-P/Gem with FOLFIRINOX for the treatment of PC have not yet reported results, retrospective analyses have explored these standard-of-care regimens with one another and/or Gem for the treatment of MPC. 11, 12, [26] [27] [28] [29] One study reported a median OS of 10.2 months with nab-P/Gem (n=189) versus 11.2 months with FOLFIRINOX (n=666) and 7 months for Gem combined with other chemotherapies (n=1,567). 11 Similar results were reported from another retrospective analysis: median OS of 11.6 months with nab-P/Gem (n=41) versus 13 months with FOLFIRINOX (n=101) and 7.5-9.1 months for Gem plus other chemotherapies (n=277). 12 A real-world analysis based on electronic medical records of patients (N=202) receiving first-line treatment for advanced PC demonstrated similar comparative effectiveness for nab-P/ Gem versus FOLFIRINOX (database persistence [proxy for OS], median, 8.6 months in both groups), despite patients in the FOLFIRINOX group being significantly younger. 27 In addition, a retrospective analysis (N=150) of patients treated at 5 cancer centers in British Columbia, Canada, found that both nab-P/Gem and FOLFIRINOX produced similar outcomes and demonstrated longer OS versus Gem alone as treatment for unresectable PC (median, 11.6 and 11.2 vs 4.1 months, respectively; P<0.001 and P=0.039). 29 Patients who received FOLFIRINOX were younger (median age, 61 vs 70 years) and fitter (ECOG PS≤1, 91% vs 54%) than those who received nab-P/Gem. 29 Collectively, the OS with nab-P/Gem observed in MPACT was consistent with the OS observed in real-world observational data sets, and nab-P/Gem was comparable in effectiveness to FOLFIRINOX.
Subsequent therapies after first-line nab-P/Gem in MPC
Many recent analyses have examined the use of second-line therapies after nab-P/Gem. 27, [30] [31] [32] [33] Patients in MPACT who received second-line therapy (n=170) after nab-P/Gem experienced a numerically longer median OS than those who did not (n=250; median total OS, 12.8 and 6.3 months, respectively). 30 The longest total OS values were observed in patients who received first-line nab-P/Gem followed by fluoropyrimidine-containing second-line regimens (n=132; median, 13.5 months); a small number (n=18) received second-line FOLFIRINOX and experienced a median total OS of 15.7 months. 30 Another retrospective analysis from the previously described Italian registry (N=250) demonstrated similar findings, that is, a median OS of 13.5 months in patients who received second-line treatment after firstline nab-P/Gem (n=122). 31 More specifically, patients who received second-line FOLFOX/XELOX (n=56), FOLFIRI (n=24), and FOLFIRINOX (n=22) had median total OS values of 12. findings have been observed in many other analyses, and the totality of data suggests that first-line nab-P/Gem followed by second-line therapy, particularly with regimens that contain a fluoropyrimidine, is feasible and beneficial to patients with advanced PC.
27,30-33
Future directions
Future directions for nab-P/Gem include studies in which the regimen has been used as a backbone therapy (ie, with another agent) in MPC (Table 3) and as a doublet in locally advanced pancreatic cancer (Table 4) . Table 5 displays a list of selected ongoing trials of nab-P/Gem with or without other agents as treatment for metastatic, locally advanced, and resectable disease.
nab-P/Gem as a backbone regimen in MPC (studies with results)
Because nab-P/Gem has demonstrated survival comparable to that with FOLFIRINOX and a more favorable toxicity profile, this regimen is commonly used as a chemotherapy backbone for other agents (Table 3) . Agents combined with nab-P/Gem are diverse and include cancer stem cell inhibitors (demcizumab, vismodegib, tarextumab, and BBI-608), those with potential immune-modulating activities (indoximod), those directed against tumor stroma (PEGPH20 and 2-0, 3-0 desulfated heparin), chemotherapies (capecitabine ± cisplatin), hormone therapy (enzalutamide), and others (erlotinib and apatorsen). In 15 studies of patients with MPC treated with nab-P/Gem combined with other agents 
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Kim (including 10 phase I trials), the median OS ranged from 6.9 to 17 months.
nab-P/Gem as a backbone regimen in MPC (studies without results)
Thirty ongoing phase II and III trials of nab-P in PC with a sample size of ≥100 were identified, including 16 MPC trials (all first line); most included an additional agent (Table 5) . For example, the phase II/III RESOLVE trial (N=326) is evaluating nab-P/Gem, with or without the Bruton tyrosine kinase inhibitor ibrutinib, as first-line treatment of MPC. 34 Based on promising results from phase I/II trials (Table 3) , a phase III trial (N=420) is investigating PEGPH20 in combination with nab-P/Gem in patients with high levels of hyaluronan, and demcizumab with nab-P/Gem is being evaluated in the phase II YOSEMITE trial (N=201). 35 Another noteworthy ongoing trial is a phase II study (N=260) of nab-P/Gem plus istiratumab (MM-141; a bispecific antibody ] receptor) for the first-line treatment of patients with MPC and high serum levels of free IGF-1. 36 Finally, whether the combination of nab-P/Gem with checkpoint inhibitors will be an effective strategy for PC is an important question, because checkpoint inhibitors have recently provided breakthrough treatment options for several tumor types and are currently being explored in a number of PC trials. Data on such combinations (eg, nab-P/Gem and nivolumab) 37 are preliminary at this point.
Neoadjuvant trials for patients with resectable, borderline resectable, or LAPC (studies with results)
Several recent studies (n=12) examined neoadjuvant nab-P/Gem as a strategy for improving R0 resection rates in resectable tumors or converting borderline resectable tumors to resectable tumors. One of the main pathologic predictors of survival after surgery is resection margin status; a negative resection margin (R0) is associated with better prognosis compared with a positive margin. Eight of the 12 studies had a total enrollment of ≥15 patients (Table 4) . Noteworthy among these is a pilot phase II study in which patients with resectable PC (N=25) were treated with neoadjuvant nab-P/Gem for 3 cycles. 38 Surgical resection was possible in 84% of patients and resulted in R0 resection in 95% of resected cases, or 80% of the intention-to-treat population. 38 The phase II GAP study also evaluated neoadjuvant nab-P/Gem for 2 cycles in patients with resectable PC (N=41). 39 After neoadjuvant treatment, 73% of the patients underwent pancreatic resection. 39 Similar results were reported from another trial of neoadjuvant nab-P/ Gem (administered for 2 cycles) in patients with resectable or borderline resectable tumors (N=16). 40 Seventy-five percent of patients underwent surgery, and R0 resection was achieved in 69% of the intention-to-treat population -92% of those who underwent surgery. The phase II NEOLAP trial (N=168) will examine the ability of neoadjuvant nab-P/Gem versus FOLFIRINOX to convert unresectable LAPC or borderline resectable tumors to resectable tumors (Table 5) . 41 Another phase II study (N=112) is comparing neoadjuvant nab-P/Gem versus FOLFIRINOX followed by resection in patients with potentially resectable tumors. 42 The randomized phase II LAPACT study (N=110) is investigating time to treatment failure in patients with unresectable LAPC treated with nab-P/Gem. Ongoing adjuvant trials for patients with resectable PC
The ongoing phase III APACT study is evaluating nab-P/Gem versus Gem monotherapy as adjuvant treatment in patients who have undergone macroscopic complete resection for non-MPC (Table 5) . 45, 46 Two other studies are also examining nab-P/Gem as adjuvant therapy: the phase II NEONAX study (N=166; nab-P/Gem as adjuvant only vs as neoadjuvant plus adjuvant) 47 and a second-line adjuvant phase III trial in patients who experienced disease relapse during Gem-based adjuvant therapy (N=300). 48 
Discussion
Multiple studies have demonstrated that first-line treatment with nab-P/Gem improves survival in patients with MPC, with OS similar to or better than that observed in MPACT. These studies have helped to confirm the dose and schedule of nab-P 125 mg/m 2 plus Gem 1,000 mg/ m 2 qw 3/4 as an effective and tolerable option for patients with MPC. Retrospective analyses of comparisons between nab-P/Gem and FOLFIRINOX suggested similar efficacy outcomes between the regimens, despite differences in patient populations; nab-P/Gem was used in a broader spectrum of patients.
Most studies demonstrated an OS benefit with nab-P/Gem regardless of age group; similarly, patients seem to derive substantial clinical benefit from nab-P/Gem regardless of PS. The demonstrated efficacy of first-line nab-P/Gem has led to a number of studies examining regimens afterward as second-line therapy. 27, [30] [31] [32] [33] These studies showed that second-line treatment after nab-P/Gem is feasible and that fluoropyrimidine-containing regimens, and not exclusively FOLFIRINOX, are appropriate options in this setting.
There are currently >100 ongoing trials (combined target enrollment >9,500 patients) assessing different nab-P regimens for the treatment of PC, and these studies will provide critical information regarding optimal combinations for specific patient populations. 49 
Conclusion
In summary, nab-P/Gem is an effective and well-tolerated regimen for patients with PC. Ongoing trials will evaluate nab-P in all stages of PC. The combination of nab-P/Gem has become a standard of care for MPC and a backbone onto which novel therapies are added in ongoing trials. Future directions in this field will revolve around improving our understanding of PC, including its molecular biology, and identifying subsets of patients that may benefit from specific treatments.
